NEW YORK – Prescient Metabiomics, a subsidiary of Prescient Medicine Holdings, and OraSure Technologies subsidiary CoreBiome said on Tuesday that they are collaborating to develop a colon cancer screening test.
The test, called LifeKit Prevent, will use microbial biomarkers to predict the development of precancerous adenomas and carcinomas. The companies said they will use shotgun metagenomic sequencing, machine learning, and AI-driven microbiome analytics to accelerate their development pipeline.
Financial terms of the collaboration were not disclosed.
"CoreBiome's DNA sequencing platform and innovative bioinformatics methods for data analysis will be critical for development of the LifeKit Prevent test," Prescient Medicine CEO Keri Donaldson said in a statement. "Prescient Metabiomics will leverage CoreBiome's discovery platform to accelerate development and validation through the FDA's Breakthrough Devices Program."